Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies

Authors: Tziomalos, Konstantinos; Athyros, Vasilios G.; Karagiannis, Asterios; Kolovou, Genovefa D.; Mikhailidis, Dimitri P.

Source: Current Drug Targets, Volume 10, Number 4, April 2009 , pp. 320-327(8)

Publisher: Bentham Science Publishers

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy

More about this publication?

Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

More like this?

In this: publication
By this: publisher
In this Subject: Pharmacology
By this author: Tziomalos, Konstantinos ; Athyros, Vasilios G. ; Karagiannis, Asterios ; Kolovou, Genovefa D. ; Mikhailidis, Dimitri P.

Content Key:

- Free

- New

- Open Access

- Subscribed

- Free Trial

Abstract:

The role of elevated triglyceride (TG) levels in the pathogenesis of atherosclerosis is controversial. Some studies suggest that TG might play a direct role in the development of vascular disease. Elevated TG levels are also associated with other vascular risk factors and may therefore represent an indirect marker of a high risk state. Another issue is that laboratory measurements of TG levels frequently show a substantial variability. Accumulating epidemiological data show that there is an independent association of TG levels with vascular risk. Some interventional studies also suggested that lowering TG levels might prevent vascular events. It appears that TG might be more important as therapeutic targets against a background of optimal low density lipoprotein cholesterol (LDL-C) levels. In this context, statins that are more effective in reducing TG levels, fibrates that can safely be combined with statins or fixed fibrate and statin combinations, as well as new, better tolerated nicotinic acid formulations might prove to be particularly beneficial.

Keywords: Triglyceride; statins; fibrates; nicotinic acid; cardiovascular disease; vascular risk

Document Type: Research article